Start of Phase I clinical trial of NIB-derived pipeline NIB-102, which was licensed to Takeda Pharmaceutical
We are pleased to inform that NIB-102, which has been licensed to Takeda Pharmaceutical Company Limited (“Takeda”), has started patient registration for Phase I clinical trial.
NIB-102 is a CAR-T cell therapy, targeting GPC3 (solid tumor antigen), equipped with NIB’s PRIME (Proliferation Inducing and Migration Enhancing) technology. Takeda has the worldwide right for development and marketing of NIB-102 (TAK-102). Please refer to the following registration details of the clinical trial.
This is the first clinical trial of a pipeline equipped with NIB’s PRIME technology.
NIB will continue to promote its R&D and business to deliver truly effective treatments to as many cancer patients as possible in near future.
Change of representative director of Noile-Immune Biotech
Noile-Immune Biotech (“NIB”) announced that, at the board of directors meeting held on September 11, 2020, Koji Tamada, NIB’s scientific founder, has been appointed as the representative director. He is expected to strengthen the management and organizational structure which will improve the company’s growth.